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Material and Methods: Using the National Cancer Data Base, 
we identified stage II seminoma patients treated with 
orchiectomy and either RT or MACT diagnosed from 1998-
2012.  Separately for stage IIA and IIB, factors affecting 
treatment modality (RT vs. MACT) were studied using a 
parsimonious multivariable logistic regression model.  
Propensity scores for treatment decision were incorporated 
into a multivariable Cox regression analysis of overall 
survival. 
 
Results: Analysis included 2,437 patients (IIA=960, IIB=812, 
IIC=665).  Median follow-up was 65 months (IQ range 34-
106).  Rates of RT utilization by stage were: IIA=78.1%, 
IIB=54.4%, IIC=4.2%.  Rates of MACT utilization by stage were: 
IIA=21.9%, IIB=45.6%, IIC=95.8%.  Median RT dose was: 
IIA=30.9 Gy (IQR 25.5-35.5) and IIB=35.5 Gy (IQR 31.1-36.0).  
For both IIA and IIB patients, later year of diagnosis, 
treatment at an academic facility, and pathologic assessment 
of lymph node(s) were associated with increased use of MACT 
vs. RT.  Also predictive for preferential use of MACT were 
Charlson-Deyo comorbidity score of 1+ and non-private 
insurance for IIA patients, and T stage of 2+ for IIB patients. 
Unadjusted 5-year survival by stage was: IIA=97.1% (95% 
confidence interval [CI] 96.1-98.1), IIB=93.9% (95% CI 92.1-
95.7), IIC=92.6% (95% CI 90.6-94.6), log-rank p=0.006.  
Factors predicative of improved survival on multivariable 
analysis included age<40, private insurance, and comorbidity 
score of zero.  For IIA patients, overall survival was improved 
with RT compared to MACT with a 5-year survival of 99.0% 
(95% CI 98.2-99.8) vs. 93.0% (95% CI 89.0-97.0).  This 
advantage persisted on multivariable analysis with a HR of 
0.22 (95% CI 0.08-0.64, p=0.005) and propensity adjusted HR 
of 0.28 (95% CI 0.09-0.86, p=0.027).  For IIB patients, 5-year 
survival was 95.2% (95% CI 92.8-97.6) for RT and 92.4% (95% 
CI 89.2-95.6) for MACT (log-rank p= 0.041).  This was not 
statistically significant on multivariable analysis with a HR of 
0.74 (95% CI 0.32-1.70, p=0.475) and propensity adjusted HR 
of 0.77 (95% CI 0.33-1.80, p=0.549).  An unadjusted Kaplan-
Meier plot by stage and treatment is given in Figure 1. 
 
 
 
 
Conclusion: In the largest cohort of stage II seminoma 
patients evaluated to date, we have identified numerous 
factors predictive for treatment selection and overall 
survival.  We have shown a survival advantage for stage IIA 
patients treated with RT compared with MACT, while no such 
survival advantage was seen for stage IIB patients. 
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Purpose or Objective: In 2009 we reported promising first 
results of a European pooled analysis which evaluated the use 
of intraoperative radiation therapy (IORT) in the treatment of 
soft tissue sarcomas. However, comparison of these results 
with non-IORT series seemed difficult, mainly because of the 
inclusion of grossly incomplete resected lesions, patients 
treated without additional external beam radiation therapy 
(EBRT) and comparatively short follow-up. Therefore we re-
analyzed our data limited to the patients who received IOERT 
preceeded or followed by EBRT after gross total resection 
with extended follow-up.  
 
Material and Methods: Three European expert centers 
participated in the current analysis. Patients with gross 
incomplete resection, missing documentation of EBRT or 
primary lesions outside the extremities were excluded, 
leaving 259 patients for analysis. Median age was 55 years 
and median tumor size 8 cm. 80% of the patients presented in 
primary situation with 81% of the tumors located in the lower 
limb. Stage at presentation was I:9%, II:47%, III:39%, IV:5%. 
Most patients showed high grade lesions (FNCLCC grade 1:9%, 
2:34%, 3:58%, predominantly liposarcoma (31%) and MFH 
(27%). IOERT was applied to the tumor bed with a median 
dose of 12 Gy using a median electron energy of 8 MeV. 
IOERT was preceeded (17%) or followed (83%) by EBRT with a 
median dose of 45 Gy in all patients. 37% of the patients 
received additional chemotherapy.  
 
Results: Median follow up was 63 months. Surgery resulted in 
free margins (R0) in 71% while 29% suffered from microscopic 
positive margins (R1). We observed 27 local failures, 
transferring into a 5-year local control rate of 86%. Univariate 
analysis revealed primary vs recurrent situation and resection 
margin as significant factors for local control but only 
resection margin (5-year LC rate 94% vs 70%, HR 3.8) 
remained significant in multivariate analysis. Distant failure 
was found in 70 patients, resulting in a 5-year distant control 
rate of 69%. Factors with significant impact on distant control 
in univariate analysis were histology, grading, resection 
margin and stage IV prior/at IOERT, but only grading and 
stage IV remained significant in multivariate analysis. 
Actuarial 5-year rates of FFTF and OS were 61% and 78%, 
respectively. Significant factors for overall survival were only 
grading and stage IV prior/at IOERT (uni- and multivariate). 
Secondary amputations were needed in 14 patients (5%) 
resulting in a final limb-preservation rate of 95%. Good 
functional outcome was achieved in 81%.  
 
Conclusion: Combination of IOERT and EBRT after limb 
sparing surgery resulted in encouraging local control and 
overall survival with excellent rates of preserved limb 
function in this unfavourable patient group. Our analysis 
identified resection margin as most important factor for local 
control while overall survival was mainly influenced by 
grading and stage IV prior/at IOERT.  
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Purpose or Objective: The AIEOP-MH89 protocol aimed to 
optimize treatment results in pediatric Hodgkin lymphoma 
compared to the previous AIEOP-MH83 protocol. Modifications 
included: involved field instead of extended field radiation 
therapy (RT) in early-stage patients (pts); anticipated RT for 
pts with a mass/thorax ratio (M/T)>0.33; enrolment of 
advanced-stage pts in SIOP HD IV protocol. 
 
Material and Methods: Between 1989-1995, 254 evaluable 
pts (median age 10 years, range 2-15 years) received the 
AIEOP-MH89 protocol. The pts were divided into 3 
chemotherapeutic groups according to the clinical stage. 
Group (GR) 1, pts in stages IA and IIA, including those with a 
mass/thorax ratio (M/T)<0.33, received 3 cycles of 
adriamycin, bleomycin, vinblastine, and imidazole 
carboxamide (ABVD). RT was given after completion of 
chemotherapy. GR 2, pts in stages IEA, IB, IA, IIA with 
M/T>0.33, IIB, IIEB, IIIA, IIIS, and IIEA, was treated with 
alternating cycles of nitrogen mustard, vincristine, 
procarbazine, and prednisone (MOPP)/ABVD. The therapeutic 
program included 2 cycles of MOPP/ABVD before radiation 
therapy and 4 cycles MOPP/ABVD after RT. GR 3, pts in 
advanced stages IIIB, IVA and IVB, was treated according to 
the SIOP HD IV-87 protocol, with 2 cycles of vincristine, 
procarbazine, prednisone, adriamycin, (OPPA) and 2 cycles of 
cyclophosphamide vincristine, procarbazine, prednisone 
(COPP) followed by RT. Pts enrolled in GR 1 and 3 were 
treated with involved field RT. Pts with positive cervical 
lymph nodes received RT to the neck. In positive axillary 
lymph nodes, RT included also the sovraclavear region. Pts 
with mediastinal disease were treated with mediastinum and 
bilateral supraclavicular fossa RT, whereas pts with 
involvement of both mediastinum and other supra 
diaphragmatic lymph nodes stations received the 
conventional mantle RT. Pts with positive single inguinal 
lymph node received also comprensive RT to omolateral iliac 
nodal stations, whereas in case of multiple subdiaphragmatic 
lymph nodes disease, bilateral iliac nodal stations irradiation 
was avoided if not directly involved. The radiation doses 
were established according to response to initial 
chemotherapy, and were the same in GR 1 and 2: pts in CR 
and ≥75% PR received 20 Gy, whereas <75% PR received 40 
Gy. GR 3 pts with CR or ≥75% PR received 20 Gy, and 36 Gy 
those with 75% PR. 
 
Results: In table 1 are reported the results in term of Overall 
Survival (OS) and Event Free Survival (EFS). Long term side 
effects of treatment were evaluated (median follow-up 
duration 16 years): 25.6% of the pts developed thyroid 
complications and 6.6% secondary malignancies. 
 
 
 
Conclusion: The AIEOP-MH89 protocol improves globally OS 
and EFS. In GR 1 OS and EFS are the same compared to the 
previous protocol, minimizing radiation exposure. In GR 2 and 
3 OS and EFS improved because of therapeutic changes. 
Analysis of delayed toxicities underlines the importance of 
long-term monitoring of pts. 
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